Compare EKSO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | PRPO |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 44.4M |
| IPO Year | 2012 | 2000 |
| Metric | EKSO | PRPO |
|---|---|---|
| Price | $11.38 | $28.15 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 58.7K | 12.3K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.76 | ★ 92.15 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | $81.23 | N/A |
| Revenue Next Year | $7.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.23 | $5.45 |
| 52 Week High | $13.50 | $29.80 |
| Indicator | EKSO | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 54.87 |
| Support Level | $9.18 | $22.96 |
| Resistance Level | $13.16 | $28.76 |
| Average True Range (ATR) | 0.97 | 1.59 |
| MACD | 0.19 | 0.11 |
| Stochastic Oscillator | 94.07 | 72.44 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.